Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer
NCT03047135Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2017
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2017; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03047135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03047135.